Logo image of OBLN

Obalon Therapeutics Inc (OBLN) Stock Fundamental Analysis

NASDAQ:OBLN - Nasdaq -

3.05  -0.19 (-5.86%)

After market: 3.12 +0.07 (+2.3%)

Fundamental Rating

2

Taking everything into account, OBLN scores 2 out of 10 in our fundamental rating. OBLN was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While OBLN seems to be doing ok healthwise, there are quite some concerns on its profitability. OBLN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OBLN has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -64.81%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -1387.25%
PM (TTM) -1391.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for OBLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -14.40, we must say that OBLN is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for OBLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.4
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

OBLN has a Current Ratio of 1.86. This is a normal value and indicates that OBLN is financially healthy and should not expect problems in meeting its short term obligations.
OBLN has a Quick Ratio of 1.86. This is a normal value and indicates that OBLN is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.86

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.15% over the past year.
OBLN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -64.65%.
OBLN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.03% yearly.
EPS 1Y (TTM)76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.43%
Revenue 1Y (TTM)-64.65%
Revenue growth 3Y-45.69%
Revenue growth 5Y-17.03%
Sales Q2Q%-100%

3.2 Future

OBLN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.38% yearly.
OBLN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 369.34% yearly.
EPS Next Y43.12%
EPS Next 2Y29.83%
EPS Next 3Y22.16%
EPS Next 5Y17.38%
Revenue Next Year953.33%
Revenue Next 2Y274.17%
Revenue Next 3Y334.11%
Revenue Next 5Y369.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OBLN Yearly Revenue VS EstimatesOBLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
OBLN Yearly EPS VS EstimatesOBLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OBLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OBLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBLN Price Earnings VS Forward Price EarningsOBLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.11
OBLN Per share dataOBLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as OBLN's earnings are expected to grow with 22.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.83%
EPS Next 3Y22.16%

More info and screens

0

5. Dividend

5.1 Amount

OBLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Obalon Therapeutics Inc

NASDAQ:OBLN (6/15/2021, 8:00:01 PM)

After market: 3.12 +0.07 (+2.3%)

3.05

-0.19 (-5.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)03-11 2022-03-11/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners45.04%
Ins Owner Change0%
Market Cap30.57M
Analysts0
Price Target18.82 (517.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.83
P/FCF N/A
P/OCF N/A
P/B 3.03
P/tB N/A
EV/EBITDA -2.11
EPS(TTM)-3.17
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.08
BVpS1.01
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1387.25%
PM (TTM) -1391.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.86
Altman-Z -14.4
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.43%
EPS Next Y43.12%
EPS Next 2Y29.83%
EPS Next 3Y22.16%
EPS Next 5Y17.38%
Revenue 1Y (TTM)-64.65%
Revenue growth 3Y-45.69%
Revenue growth 5Y-17.03%
Sales Q2Q%-100%
Revenue Next Year953.33%
Revenue Next 2Y274.17%
Revenue Next 3Y334.11%
Revenue Next 5Y369.34%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A